Trials / Completed
CompletedNCT03450720
Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis
Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of GLPG2737 Administered as Oral Suspension in Male Subjects With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single dose, open label study in adult male subjects with cystic fibrosis to investigate the pharmacokinetics, safety and tolerability of GLPG2737.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG2737 single dose | GLPG2737 oral suspension, single dose |
Timeline
- Start date
- 2017-06-28
- Primary completion
- 2017-08-16
- Completion
- 2017-08-16
- First posted
- 2018-03-01
- Last updated
- 2018-03-19
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03450720. Inclusion in this directory is not an endorsement.